Meet Alexander Schuth, M.D., the Chief Operating and Financial Officer of Denali Therapeutics. He joined Denali in 2015 and has a solid track record in the biotech world, being a key player since the company was founded. Before that, he...

Meet Alexander Schuth, M.D., the Chief Operating and Financial Officer of Denali Therapeutics. He joined Denali in 2015 and has a solid track record in the biotech world, being a key player since the company was founded. Before that, he worked at Genentech, where he took on many important roles that helped shape drug development and partnerships. In March 2022, he added the Chief Financial Officer title to his responsibilities. Dr. Schuth has a unique blend of experience in both science and finance, with an M.D. from Charité Medical School in Germany and an M.B.A. from The Wharton School. He also spent time in investment banking, which gives him a strong grip on the financial side of biotech. His focus is on driving Denali's mission to develop treatments for serious diseases, and he currently serves on the board of a biopharmaceutical company, Molecular Health.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Denali Therapeutics Inc. CEOs

D

Alexander Schuth, M.D.

CEO of Denali Therapeutics Inc.

Sector of Economy

Healthcare

CEO of Denali Therapeutics Inc. for

3 years 1 month (May 2022 - Present)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Alexander Schuth, M.D.

B

John Evans

CEO of Beam Therapeutics

2023 Compensation

Stock

$0.00

Salary

$685.00K

Bonus

$431.55K

Other

$17.68K

Total Holdings

$24.88M

Holdings

See how much did Alexander Schuth, M.D. make over time.

As of recent reports, Dr. Schuth holds a substantial stake in Denali Therapeutics, Inc., the company he helped establish and grow. His shares have fluctuated as the company navigated various phases in the biotech industry. At one point, his holdings...

As of recent reports, Dr. Schuth holds a substantial stake in Denali Therapeutics, Inc., the company he helped establish and grow. His shares have fluctuated as the company navigated various phases in the biotech industry. At one point, his holdings represented a significant portion of his wealth, showcasing his belief in Denali's potential. Currently, his stock ownership continues to reflect his commitment to the company's long-term vision. The value of his holdings aligns closely with Denali's ongoing developments and successes in the market, emphasizing his direct stake in the company's progress.

Mar 17, 2025

D

shares

DNLI @ $15.44

Total Stock Sold

$17.04M

DNLI

$17.04M

412,880 DNLI shares

What if they kept their stock?

If Alexander Schuth, M.D. didn't sell their stock, today they would have:
Extra DNLI412,880 shares worth $11.15M.
This is -34.6% and $5.90M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Alexander Schuth, M.D..

DNLI

$200.78K

DNLI at $24.04/share

Aug 20, 2024

Sale

DNLI

$52.01K

DNLI at $22.89/share

Aug 13, 2024

Sale

DNLI

$399.20K

DNLI at $17.48/share

Feb 13, 2024

Sale

DNLI

$193.76K

DNLI at $19.43/share

Jan 5, 2024

Sale

DNLI

53,720 shares

DNLI

Jan 3, 2024

Received

DNLI

$58.43K

DNLI at $23.17/share

Aug 23, 2023

Sale

DNLI

$55.98K

DNLI at $22.59/share

Aug 21, 2023

Sale

DNLI

$65.61K

DNLI at $23.67/share

Aug 14, 2023

Sale

DNLI

$68.99K

DNLI at $24.18/share

Aug 10, 2023

Sale

DNLI

$587.22K

DNLI at $29.81/share

Jul 17, 2023

Sale

Compensation History

See how much did Alexander Schuth, M.D. make over time.

In 2022, Dr. Schuth's total compensation package was $747,200. This included a base salary of $500,000 and a bonus of $225,000, reflecting his performance and the company's success. He did not have any vested stock or options in 2022, as his focus has been on the company's growth rather than immediate stock gains. His compensation illustrates a pay-for-performance philosophy, aligning his financial rewards with Denali's achievements. Overall, his compensation indicates a strong emphasis on performance linked directly to the company's strategic goals.

Year

2022

Total Compensation

$737.20K

Salary

$500.00K

Board Justification

The compensation philosophy focuses on pay for performance, aligning executive compensation with the achievement of strategic business goals and shareholder interests.

Bonus

$225.00K

Board Justification

The annual bonus was based on the achievement of corporate goals, with a funding percentage of 100% of target due to meeting 75% of the goals set for 2022.

Other

$12.20K

Board Justification

Other compensation includes employer 401(k) matching contributions.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2022 as the focus was on options and RSUs granted in previous years.

Performance Metrics

The performance metrics included achieving corporate goals related to product development and strategic initiatives.

Other Denali Therapeutics Inc. CEOs

Here are other CEOs of Denali Therapeutics Inc.

Steve Krognes

Ex-CEO of Denali Therapeutics Inc.

January 2021 - May 2022